Atypical antipsychotics: New drugs, new challenges
Manu Mathews, MD
Department of Psychiatry and Psychology, Cleveland Clinic
David J. Muzina, MD
Vice Chair for Research and Education, Director of the Bipolar Disorders Research Unit; and Director of Adult Inpatient Services, Department of Psychiatry and Psychology, Cleveland Clinic
Address: David J. Muzina, MD, Department of Psychiatry and Psychology, P57, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail:email@example.com
Dr. Muzina has disclosed that he has received honoraria from AstraZeneca for consulting, and from AstraZeneca, Pfizer, Eli Lilly, GlaxoSmithKline, the France Foundation, CME Inc, and The Peer Group for teaching and speaking.
ABSTRACTCompared with the first-generation, or "typical" antipsychotic drugs, second-generation or atypical antipsychotics cause fewer extrapyramidal (motor) problems, but they pose new challenges, as they often contribute to metabolic disturbances such as weight gain, hyperlipidemia, insulin resistance, and type 2 diabetes mellitus. Patients taking atypical antipsychotics should be monitored for glycemic and cardiovascular risk factors and should receive treatment for such problems as they arise.